{"id":3582,"date":"2026-11-17T15:22:07","date_gmt":"2026-11-17T15:22:07","guid":{"rendered":"https:\/\/allesleypharmacy.co.uk\/pharmacy\/?p=3582"},"modified":"2026-11-17T15:22:07","modified_gmt":"2026-11-17T15:22:07","slug":"new-treatment-option-approved-for-bladder-cancer-patients-in-england-and-wales","status":"publish","type":"post","link":"https:\/\/allesleypharmacy.co.uk\/pharmacy\/new-treatment-option-approved-for-bladder-cancer-patients-in-england-and-wales\/","title":{"rendered":"New Treatment Option Approved for Bladder Cancer Patients in England and Wales"},"content":{"rendered":"<p>Astellas Pharma has announced that the National Institute for Health and Care Excellence (NICE) has recommended a new treatment combination for adults with a specific type of <a href=\"https:\/\/allesleypharmacy.co.uk\/pharmacy\/product\/nitrofurantoin\/\" data-internallinksmanager029f6b8e52c=\"54\" title=\"Nitrofurantoin\">bladder<\/a> cancer called muscle-invasive bladder cancer (MIBC) in England and Wales. The treatment combines two drugs: pembrolizumab (brand name KEYTRUDA) and enfortumab vedotin (brand name PADCEV). This combination can now be used before surgery to help shrink the tumor, and it can also be continued after surgery to reduce the risk of the cancer coming back. Patients do not need to be able to receive the standard <a href=\"https:\/\/allesleypharmacy.co.uk\/pharmacy\/product\/methotrexate\/\" data-internallinksmanager029f6b8e52c=\"48\" title=\"Methotrexate\">chemotherapy<\/a> drug cisplatin, which has traditionally been used before surgery but can cause side effects in some people. The recommendation applies to patients within the approved uses of these drugs. NICE has confirmed that this combination is both effective and cost-efficient, making it a suitable option for routine use on the NHS. Bladder cancer causes around 5,900 deaths in the UK each year, and MIBC is an aggressive form where the cancer spreads into the muscle surrounding the bladder. Even with treatment aimed at curing the disease, there is a high chance the cancer may return or progress. NICE has highlighted the need for treatments like this combination that can slow the disease and help patients live longer, especially for those who cannot receive cisplatin. Dr. Tim Patel, Medical Director at Astellas UK, stated, &#8220;We welcome NICE\u2019s recommendation for adults with muscle-invasive bladder cancer. This is an important step in expanding treatment options around surgery, including for people who are unable to receive cisplatin-based chemotherapy.&#8221; He also expressed the company\u2019s commitment to working with the NHS and bladder cancer organizations to ensure patients have timely access to this treatment if they may benefit from it. Enfortumab vedotin (PADCEV) is a targeted therapy that works by attaching to a protein called Nectin-4, which is found in high levels in bladder cancer cells. This drug is already approved in several countries, including Europe, for treating bladder cancer and other urinary tract cancers. In the European Union, the combination of enfortumab vedotin and pembrolizumab is already approved for adults with MIBC who may undergo surgery, regardless of whether they can receive cisplatin.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Astellas Pharma has announced that the National Institute for Health and Care Excellence (NICE) has recommended a new treatment combination [&hellip;]<\/p>\n","protected":false},"author":0,"featured_media":3583,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"default","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","ast-disable-related-posts":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"footnotes":""},"categories":[543],"tags":[],"class_list":["post-3582","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-pharmaceutical-news"],"_links":{"self":[{"href":"https:\/\/allesleypharmacy.co.uk\/pharmacy\/wp-json\/wp\/v2\/posts\/3582","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/allesleypharmacy.co.uk\/pharmacy\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/allesleypharmacy.co.uk\/pharmacy\/wp-json\/wp\/v2\/types\/post"}],"replies":[{"embeddable":true,"href":"https:\/\/allesleypharmacy.co.uk\/pharmacy\/wp-json\/wp\/v2\/comments?post=3582"}],"version-history":[{"count":1,"href":"https:\/\/allesleypharmacy.co.uk\/pharmacy\/wp-json\/wp\/v2\/posts\/3582\/revisions"}],"predecessor-version":[{"id":3588,"href":"https:\/\/allesleypharmacy.co.uk\/pharmacy\/wp-json\/wp\/v2\/posts\/3582\/revisions\/3588"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/allesleypharmacy.co.uk\/pharmacy\/wp-json\/wp\/v2\/media\/3583"}],"wp:attachment":[{"href":"https:\/\/allesleypharmacy.co.uk\/pharmacy\/wp-json\/wp\/v2\/media?parent=3582"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/allesleypharmacy.co.uk\/pharmacy\/wp-json\/wp\/v2\/categories?post=3582"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/allesleypharmacy.co.uk\/pharmacy\/wp-json\/wp\/v2\/tags?post=3582"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}